Healthy Subjects Clinical Trial
Official title:
An Open-Label, Single-Center, Single-Dose, Phase I Study to Assess the Mass Balance of [14C] SY-5007 in Healthy Male Subjects in China
This is a single-center, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled SY-5007 administered orally.
Status | Not yet recruiting |
Enrollment | 8 |
Est. completion date | June 1, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: 1. Fully informed, able to communicate effectively with researchers, agree to abide by the protocol and trial management regulations, and voluntarily sign the written Informed Consent Form (ICF); 2. Healthy adult males aged 18 to 50 years at the time of signing the ICF, with no plans for reproduction or sperm donation within the past 2 years; 3. Weight = 50 kg and body mass index (BMI) between 18 and 26 kg/m2; 4. Subjects of reproductive capability agree to employ effective contraceptive measures with their sexual partners during the study period and for 2 years following the end of the study. Exclusion Criteria: Subjects meeting any of the following criteria are ineligible for participation in this study: 1. History of allergies (such as allergies to two or more drugs, foods, or pollen, or individuals prone to skin hives or allergic reactions). 2. Positive for hepatitis B surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, or positive for syphilis treponemal and non-treponemal antibodies during screening. 3. Abnormal clinically significant vital signs, physical examinations, laboratory tests, or electrocardiograms at screening. 4. Gastrointestinal, hepatic, or renal diseases that may affect drug pharmacokinetics as assessed by the investigator at screening. 5. History of drug abuse or illicit drug use within 12 months prior to the first dose administration, or positive urine drug screening test during screening. 6. Underwent major surgery within 6 months prior to the first dose administration, or planned to undergo surgery during the trial period. 7. History of any clinically significant illness within 3 months prior to the first dose administration or conditions deemed by the investigator to potentially affect trial outcomes, including but not limited to cardiovascular, endocrine, nervous, respiratory, digestive, urinary, hematologic, immune, or psychiatric disorders. 8. Average daily smoking of more than 5 cigarettes within 3 months prior to the first dose administration, or unwillingness to discontinue use of any tobacco products during the trial. 9. Regular alcohol consumption within 3 months prior to the first dose administration [defined as consuming more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol liquor or 150mL of 12% alcohol wine)], or inability to abstain from alcohol during the trial, or positive alcohol breath test during screening. 10. History of blood donation or significant blood loss (= 300mL) within 3 months prior to the first dose administration, or use of blood products or blood transfusion within 1 month prior to the first dose administration. 11. Participation in other drug or medical device clinical trials within 3 months prior to the first dose administration (excluding screen failures), or prior use of the investigational drug. 12. Vaccination within 1 month prior to the first dose administration. 13. Use of any prescription drugs, over-the-counter drugs, supplements, or herbal remedies within 2 weeks prior to the first dose administration (if the half-life [t1/2] of the drug can be confirmed, a washout period of 5 times of t1/2 is required). 14. Habitual consumption of more than 8 cups (1 cup = 250mL) of tea, coffee, or caffeinated beverages and unable to abstain from consumption within 48 hours prior to the first dose administration and during the trial. 15. Special dietary requirements or difficulty swallowing. 16. Habitual constipation or previous difficulty with bowel movements. 17. Difficulty with blood collection, history of fainting with needles, or intolerance to venipuncture. 18. Engagement in occupations requiring prolonged exposure to radioactive conditions; or significant exposure to radiation within 1 year prior to the trial (e.g., 2 chest/abdominal CT scans, or 3 other types of X-ray examinations). 19. History of definite neurological or psychiatric disorders, including dementia or seizures diagnosed for any reason. 20. Other conditions deemed unsuitable for participation in this study by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Friendship Hospital, Capital Medical University | Beijing |
Lead Sponsor | Collaborator |
---|---|
Shouyao Holdings (Beijing) Co. LTD |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total radioactivity in plasma PK: Cmax | Highest radioactivity observed plasma concentration | At pre-dose and up to 2 weeks post-dose | |
Primary | Total radioactivity in plasma PK: Tmax | Time to reach the Cmax | At pre-dose and up to 2 weeks post-dose | |
Primary | Total radioactivity in plasma PK: AUC0-t | Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration | At pre-dose and up to 2 weeks post-dose | |
Primary | Total radioactivity in plasma PK: t½ | Defined as apparent plasma terminal phase disposition half-life | At pre-dose and up to 2 weeks post-dose | |
Primary | Total radioactivity in plasma PK: CL/F | Defined as apparent total body clearance | At pre-dose and up to 2 weeks post-dose | |
Primary | Whole blood to plasma total radioactivity ratio | To evaluate the extent of distribution of total radioactivity into blood cells | At pre-dose and up to 2 weeks post-dose | |
Primary | Cumulative total radioactivity in urine and faeces | Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted (Ae) expressed as a percentage of the administered dose (%Ae) | At pre-dose and up to 2 weeks post-dose | |
Primary | Metabolic profiling in plasma, urinary and fecal excretion | To characterize the metabolic profile and identify circulating and excreted metabolites of SY-5007 using liquid chromatography with mass spectral detection. | At pre-dose and up to 2 weeks post-dose | |
Secondary | Cmax of SY-5007 and its metabolites | Defined as maximum observed plasma concentration | At pre-dose and up to 2 weeks post-dose | |
Secondary | Tmax of SY-5007 and its metabolites | Defined as time to maximum plasma concentration | At pre-dose and up to 2 weeks post-dose | |
Secondary | AUC0-t of SY-5007 and its metabolites | Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration | At pre-dose and up to 2 weeks post-dose | |
Secondary | t½ of SY-5007 and its metabolites | Defined as apparent plasma terminal phase disposition half-life | At pre-dose and up to 2 weeks post-dose | |
Secondary | CL/F of SY-5007 and its metabolites | Defined as apparent total body clearance | At pre-dose and up to 2 weeks post-dose | |
Secondary | Incidence of adverse events | To evaluate the safety of a single oral dose of 160 mg of SY-5007 | At pre-dose and up to 2 weeks post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |